Wedbush reiterated an Outperform rating on Apogee Therapeutics and raised its 12-month price target to $135 from $120, a 12.5% increase. The note is supportive for the clinical-stage biotech name but contains no new operating data or trial results. The update is likely to influence sentiment more than broader market conditions.
Wedbush reiterated an Outperform rating on Apogee Therapeutics and raised its 12-month price target to $135 from $120, a 12.5% increase. The note is supportive for the clinical-stage biotech name but contains no new operating data or trial results. The update is likely to influence sentiment more than broader market conditions.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
